



## DISCLOSURES AND RESOLUTION OF CONFLICT OF INTEREST

The following faculty have indicated that they do not have any relevant financial relationships with ineligible companies\* to disclose, and that their presentation or discussion will not include off-label or unapproved product usage.

**Sergui Darabant, M.D.**  
**Eduardo Icaza, M.D.**  
**Sarah Joseph, M.D.**  
**Maria N. Kyriacou, M.D.**  
**Elise McCormack-Granja, M.D.**

**Adaeze Ohaeto, APRN**  
**Rachel Rohaidy, M.D.**  
**Christian Suarez Fuentes, M.D.**  
**Michael Swartzon, M.D.**  
**Nada Wakim, Ph.D., R.N.**

---

**Manmeet Ahluwalia, M.D.**, faculty and planner of this educational activity, is a researcher for AstraZeneca, Bayer, Bristol Myers Squibb, Incyte, Merck, Mimivax, Novocure and Pharmacoclytics. He is a consultant for Apollomics, Bayer, Caris Life Sciences, Cellularity, GSK, Insightec, Janssen, Kiyatec, Novocure, Prelude, Pyramid Biosciences, SDP Oncology, Tocagen, ViewRay, Voyager Therapeutics, Xofig, Varian Medical System and Cairn Therapeutics. He has individual stocks/stock options with Cytodyn, Doctible, Medinnovate Advisors LLC, and Mimivax. He has indicated that the presentation or discussions will not include off-label or unapproved product usage.

**Angel R. Alejandro, M.D.**, faculty for this educational activity, is an advisor for Novo Nordisk and is on the speaker's bureau with Lilly and Boehringer Ingelheim. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

**Reuven Bromberg, M.D.**, faculty for this educational activity, is an advisor for Janssen and is on the speaker's bureau for AstraZeneca, Medexus and Abbvie. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

**Felipe De Los Rios De La Rosa, M.D.**, faculty for this educational activity, is on the speakers' bureau with AstraZeneca, Brillinta and Andexxa. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

**Theodore Feldman, M.D.**, faculty for this educational activity, is on the speakers bureau with Novo Nordisk, AstraZeneca, Eli Lilly and Boehringer Ingelheim. He holds an executive role with Rightway Healthcare and has ownership in Cadence Solutions.

**Timothy Gauthier, PharmD**, faculty for this educational activity, is a consultant for Pattern Biosciences (formerly Klaris diagnostics), an independent contractor for MeMED and a consultant for Pfizer and DoseMeRx by Tabula Rasa. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

**Marcus St. John, M.D.**, faculty for this educational activity, is on the speakers' bureau with Zoll. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

**Harneet Walia, M.D.**, faculty for this educational activity has received research funding from Sommetrics and is an advisor for Resmed and Idorsia. She has indicated that the presentation or discussion will not include off-label or unapproved product usage.

All of the relevant financial relationships listed for these individual(s) have been mitigated.

---

Non-faculty contributors and others involved in the planning, development and editing/review of the content do not have relevant financial relationships to disclose with ineligible companies\*.

---

*\*Ineligible companies - Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.*